Evan Rogers

812 total citations
25 papers, 267 citations indexed

About

Evan Rogers is a scholar working on Pulmonary and Respiratory Medicine, Molecular Biology and Cancer Research. According to data from OpenAlex, Evan Rogers has authored 25 papers receiving a total of 267 indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Pulmonary and Respiratory Medicine, 12 papers in Molecular Biology and 11 papers in Cancer Research. Recurrent topics in Evan Rogers's work include Lung Cancer Treatments and Mutations (16 papers), Cancer Genomics and Diagnostics (7 papers) and Lung Cancer Research Studies (5 papers). Evan Rogers is often cited by papers focused on Lung Cancer Treatments and Mutations (16 papers), Cancer Genomics and Diagnostics (7 papers) and Lung Cancer Research Studies (5 papers). Evan Rogers collaborates with scholars based in United States, South Korea and United Kingdom. Evan Rogers's co-authors include Dayong Zhai, Wei Deng, Xin Zhang, Brion W. Murray, Armin Graber, Alexander Drilon, Dong Ki Lee, Vivek Subbiah, Ana María López‐Parra and J. Jean Cui and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Cancer Research.

In The Last Decade

Evan Rogers

21 papers receiving 265 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Evan Rogers United States 8 188 154 142 52 27 25 267
C. Massard France 11 130 0.7× 87 0.6× 141 1.0× 55 1.1× 21 0.8× 40 325
Linh T. Nguyen United States 7 98 0.5× 76 0.5× 192 1.4× 45 0.9× 33 1.2× 17 275
G. K. Schwartz United States 11 95 0.5× 188 1.2× 202 1.4× 28 0.5× 38 1.4× 29 351
Sonia Garofalo Italy 6 126 0.7× 189 1.2× 145 1.0× 50 1.0× 34 1.3× 7 364
Olen Stephens New Zealand 5 118 0.6× 132 0.9× 80 0.6× 46 0.9× 30 1.1× 7 243
Bharani Dharan United States 6 120 0.6× 144 0.9× 152 1.1× 59 1.1× 31 1.1× 10 324
Marc Chioda United States 9 185 1.0× 181 1.2× 77 0.5× 42 0.8× 25 0.9× 14 276
Jiadi Gan China 11 183 1.0× 175 1.1× 93 0.7× 61 1.2× 21 0.8× 19 292
Mike Lau United Kingdom 9 138 0.7× 197 1.3× 173 1.2× 27 0.5× 11 0.4× 25 351
Tanya Ahmad United Kingdom 4 93 0.5× 91 0.6× 152 1.1× 57 1.1× 28 1.0× 10 262

Countries citing papers authored by Evan Rogers

Since Specialization
Citations

This map shows the geographic impact of Evan Rogers's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Evan Rogers with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Evan Rogers more than expected).

Fields of papers citing papers by Evan Rogers

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Evan Rogers. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Evan Rogers. The network helps show where Evan Rogers may publish in the future.

Co-authorship network of co-authors of Evan Rogers

This figure shows the co-authorship network connecting the top 25 collaborators of Evan Rogers. A scholar is included among the top collaborators of Evan Rogers based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Evan Rogers. Evan Rogers is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Rogers, Evan, Vishwanath Sankarasubramanian, Ehsan Mirzakhalili, et al.. (2025). Longitudinal Changes in Sensory Processing and Clinical Outcomes During Spinal Cord and Dorsal Root Ganglion Stimulation to Treat Chronic Pain: A Pilot Study. Journal of Pain Research. Volume 18. 4455–4470.
2.
Cui, J. Jean, Evan Rogers, Dayong Zhai, et al.. (2025). Abstract 5608: Design and discovery of BH-30643: A novel, reversible, mutant-selective macrocyclic EGFR inhibitor invulnerable to common resistance mutations. Cancer Research. 85(8_Supplement_1). 5608–5608.
3.
4.
Zhai, Dayong, Danan Li, Zhenping Wang, et al.. (2024). Abstract 5944: Discovery of BH-30236: A novel macrocyclic CLK inhibitor targeting alternative splicing in cancers. Cancer Research. 84(6_Supplement). 5944–5944. 1 indexed citations
5.
Murray, Brion W., Dayong Zhai, Wei Deng, et al.. (2021). TPX-0131, a Potent CNS-penetrant, Next-generation Inhibitor of Wild-type ALK and ALK-resistant Mutations. Molecular Cancer Therapeutics. 20(9). 1499–1507. 63 indexed citations
6.
Drilon, Alexander, Dayong Zhai, Evan Rogers, et al.. (2020). The next-generation RET inhibitor TPX-0046 is active in drug-resistant and naïve RET-driven cancer models.. Journal of Clinical Oncology. 38(15_suppl). 3616–3616. 45 indexed citations
7.
8.
Drilon, Alexander, Dayong Zhai, Wei Deng, et al.. (2019). Abstract 442: Repotrectinib, a next generation TRK inhibitor, overcomes TRK resistance mutations including solvent front, gatekeeper and compound mutations. Cancer Research. 79(13_Supplement). 442–442. 25 indexed citations
9.
10.
Zhai, Dayong, Evan Rogers, Xin Zhang, et al.. (2019). Abstract 1325: TPX-0022, a polypharmacology inhibitor of MET/CSF1R/SRC inhibits tumor growth by promoting anti-tumor immune responses. Cancer Research. 79(13_Supplement). 1325–1325. 6 indexed citations
11.
12.
Drilon, Alexander, Evan Rogers, Dayong Zhai, et al.. (2019). TPX-0046 is a novel and potent RET/SRC inhibitor for RET-driven cancers. Annals of Oncology. 30. v190–v191. 41 indexed citations
13.
Zhai, Dayong, et al.. (2018). Abstract B185: TPX-0005, a supreme ROS1 inhibitor, overcomes crizotinib-resistant ROS1 mutations including solvent front mutation G2032R and gatekeeper mutation L2026M. Molecular Cancer Therapeutics. 17(1_Supplement). B185–B185. 1 indexed citations
14.
Zhai, Dayong, et al.. (2018). Abstract B186: TPX-0005, a polypharmacology inhibitor, overcomes ALK treatment resistance from acquired mutations, bypass signaling, and EMT. Molecular Cancer Therapeutics. 17(1_Supplement). B186–B186. 3 indexed citations
15.
Zhai, Dayong, et al.. (2017). P3.02a-009 TPX-0005: A Multi-Faceted Approach to Overcoming Clinical Resistances from Current ALK or ROS1 Inhibitor Treatment in Lung Cancer. Journal of Thoracic Oncology. 12(1). S1164–S1165. 4 indexed citations
16.
Zhai, Dayong, et al.. (2017). Abstract 3161: TPX-0005, an ALK/ROS1/TRK inhibitor, overcomes multiple resistance mechanisms by targeting SRC/FAK signaling. Cancer Research. 77(13_Supplement). 3161–3161. 7 indexed citations
17.
Deng, Wei, David C.S. Huang, Dayong Zhai, Evan Rogers, & Jean Cui. (2017). Abstract 3168: Overcoming acquired drug resistance by TPX-0005, an ALK, ROS1 and pan-TRK inhibitor. Cancer Research. 77(13_Supplement). 3168–3168. 1 indexed citations
18.
19.
20.
Zhai, Dayong, et al.. (2016). Abstract 2132: The novel, rationally-designed, ALK/SRC inhibitor TPX-0005 overcomes multiple acquired resistance mechanisms to current ALK inhibitors. Cancer Research. 76(14_Supplement). 2132–2132. 10 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by C. Massard Breakdown of academic impact, for papers by Linh T. Nguyen Breakdown of academic impact, for papers by G. K. Schwartz Breakdown of academic impact, for papers by Sonia Garofalo Breakdown of academic impact, for papers by Olen Stephens Breakdown of academic impact, for papers by Bharani Dharan Breakdown of academic impact, for papers by Marc Chioda Breakdown of academic impact, for papers by Jiadi Gan Breakdown of academic impact, for papers by Mike Lau Breakdown of academic impact, for papers by Tanya Ahmad
Rankless by CCL
2026